

Jeffrey CH Chan

jeffrey.ch.chan@cls.com
+852 2600 7950

Summer Qian

+852 2600 8639

31 March 2024

China Technology

Reuters 0354.HK
Bloomberg 354 HK

Priced on 28 March 2024
HS CEI @ 5,810.8

12M hi/lo HK\$6.83/4.31

12M price target HK\$6.30
±% potential +33%

Shares in issue 2,846.6m
Free float (est.) 88.4%

Market cap US\$1.8bn

3M ADV US\$15.8m

Major shareholders

Yuhong Chen 11.6%
UBS Group 7.6%

Blended ESG Score (%)*

Overall 51.7
Country average 52.9
GEM sector average 60.4

*Click to visit company page on cls.com for details

Stock performance (%)



Source: Bloomberg

Efficiency improved

Looking for more margin improvement amid sales uncertainty

Chinasoft Intl (CSI) reported its 2023 results with revenue and NP both declining. On the positive side its GPM and NPM expanded YoY with improving project delivery efficiency and as it cut staff numbers; we expect its margin to continue to improve in 2024. We see CSI's key strategies as maintaining a good relationship with Huawei and increasing its exposure to SOE companies. We revise our forecast, cutting our target price from HK\$7.70 to HK\$6.30, but maintain our BUY rating.

Recap of 2023 revenue

2023 revenue declined by 14.4% YoY to Rmb17,117m, primarily due to softer demand from key clients (including Huawei/HSBC/Tencent down 21.3%/31.8%/31.1% YoY), but this was offset slightly by increased revenue from telecom companies and SOEs. By segment, revenue from its traditional IT outsourcing business (62.3% of sales) was down 24.5% YoY, while cloud intelligence group (37.7% of sales) was down slightly by 2.5% YoY.

Profit down but margin improved

CSI's overall margin improved in 2023. Its GPM rose 40bps to 23.4% (beating consensus by 40bps but missing to our estimate by 80bps). NP of Rmb713m was down 6.1% YoY, and missed to consensus/our forecast by -23.2%/-14.3%; but its NPM increased from 3.8% to 4.2%. The major reasons for its margin improvement: (1) CSI has made strategic adjustments to focus on new business expansion with higher GPMs, and has ceased some low-GPM business; (2) improvement in project delivery efficiency; and (3) lowering its staff from 82,140 in 2022 to 69,976 in 2023 (-14.8% YoY). We expect CSI to continue to improve its margin in 2024.

Keeping a good relationship with Huawei and expand SOE exposure

Amidst the uncertain economic recovery and external environment, partnering with Huawei should remain a key strategy. CSI has multiple relationships with Huawei, including the cross-selling of Huawei Cloud and Huawei's all-in-one AI server, the implementation of MetaERP, OpenHarmony and IoT projects, and it also leveraging Huawei's AI-related capabilities to launched an AI application platform to provide solutions for different industries. Apart from Huawei, more digitalisation projects with SOEs and telecom companies is another path to grow its revenue.

Maintain BUY

We factor-in its 2023 results and revise our forecasts. We lower our target price from HK\$7.70 to HK\$6.30, based on a 14.5x PE 25CL (unchanged), largely in-line with CSI's average forward 12-month PE. We continue to like CSI as a proxy to Huawei in the H-share market and we expect it to be benefit with Huawei's continued expansion to its software ecosystem. We maintain our BUY recommendation.

Financials

Year to 31 December	22A	23A	24CL	25CL	26CL
Revenue (Rmbm)	20,005	17,117	18,878	21,342	23,782
Rev forecast change (%)	-	-	(12.4)	(13.2)	(14.8)
Net profit (Rmbm)	759	713	884	1,104	1,384
NP forecast change (%)	-	-	(19.4)	(22.7)	(22.6)
EPS (Rmb)	0.25	0.25	0.31	0.39	0.49
CL/consensus (9) (EPS%)	-	-	82	82	82
EPS growth (% YoY)	(34.4)	(0.5)	24.0	24.9	25.3
PE (x)	16.1	17.4	14.0	11.2	9.0
Dividend yield (%)	0.7	1.2	1.5	1.8	2.3
ROE (%)	6.4	6.0	7.2	8.3	9.4
Net debt/equity (%)	(25.4)	(6.6)	(13.0)	(17.7)	(23.5)

Source: www.cls.com

Financials at a glance

Year to 31 December	2022A	2023A	2024CL	(% YoY)	2025CL	2026CL
Profit & Loss (Rmbm)						
Revenue	20,005	17,117	18,878	10.3	21,342	23,782
Cogs (ex-D&A)	(14,905)	(12,688)	(14,069)		(15,886)	(17,643)
Gross Profit (ex-D&A)	5,100	4,429	4,809	8.6	5,455	6,140
SG&A and other expenses	(3,870)	(3,301)	(3,613)		(4,020)	(4,409)
Op Ebitda	1,230	1,127	1,196	6.1	1,435	1,731
Depreciation/amortisation	(500)	(426)	(300)		(251)	(221)
Op Ebit	731	702	897	27.8	1,184	1,510
Net interest inc/(exp)	(113)	(203)	(190)		(181)	(172)
Other non-Op items	212	235	245	4.2	185	151
Profit before tax	830	734	952	29.7	1,189	1,490
Taxation	(71)	(21)	(66)		(82)	(103)
Profit after tax	759	713	886	24.3	1,107	1,387
Minority interest	1	1	(2)		(2)	(3)
Net profit	759	713	884	24	1,104	1,384
Adjusted profit	759	713	884	24	1,104	1,384
Cashflow (Rmbm)						
Operating profit	731	702	897	27.8	1,184	1,510
Depreciation/amortisation	500	426	300	(29.6)	251	221
Working capital changes	(683)	(1,109)	(219)		(434)	(391)
Other items	218	370	179	(51.5)	103	49
Net operating cashflow	765	388	1,157	198.4	1,104	1,389
Capital expenditure	(204)	(394)	(193)		(221)	(166)
Free cashflow	561	(6)	964		883	1,223
M&A/Others	(446)	179	0		0	0
Net investing cashflow	(650)	(214)	(193)		(221)	(166)
Increase in loans	(101)	(31)	0		0	0
Dividends	(80)	0	0		0	0
Net equity raised/other	(601)	(1,474)	(190)		(181)	(172)
Net financing cashflow	(781)	(1,505)	(190)		(181)	(172)
Incr/(decr) in net cash	(666)	(1,332)	774		702	1,051
Exch rate movements	114	114	114	0	114	114
Balance sheet (Rmbm)						
Cash & equivalents	5,005	3,788	4,676	23.4	5,493	6,659
Accounts receivable	6,157	6,092	6,272	3	6,648	7,077
Other current assets	2,439	3,065	3,298	7.6	3,624	3,779
Fixed assets	1,119	1,151	1,149	(0.1)	1,105	1,018
Investments	485	429	429	0	429	429
Intangible assets	1,124	1,180	1,217	3.1	1,296	1,369
Other non-current assets	636	1,363	1,221	(10.4)	1,156	1,115
Total assets	16,965	17,068	18,262	7	19,751	21,446
Short-term debt	766	735	735	0	735	735
Accounts payable	2,043	1,663	1,822	9.6	2,046	2,195
Other current liabs	744	565	600	6.2	643	687
Long-term debt/CBs	1,162	2,282	2,282	0	2,282	2,282
Provisions/other LT liabs	114	57	57	0	57	57
Shareholder funds	12,110	11,742	12,741	8.5	13,960	15,459
Minorities/other equity	25	24	26	7.5	28	31
Total liabs & equity	16,965	17,068	18,263	7	19,751	21,446
Ratio analysis						
Revenue growth (% YoY)	8.7	(14.4)	10.3		13.0	11.4
Ebitda margin (%)	6.2	6.6	6.3		6.7	7.3
Ebit margin (%)	3.7	4.1	4.7		5.5	6.3
Net profit growth (%)	(33.2)	(6.1)	24.0		24.9	25.3
Op cashflow growth (% YoY)	(20.5)	(49.3)	198.4		(4.6)	25.8
Capex/sales (%)	1.0	2.3	1.0		1.0	0.7
Net debt/equity (%)	(25.4)	(6.6)	(13.0)		(17.7)	(23.5)
Net debt/Ebitda (x)	-	-	-		-	-
ROE (%)	6.4	6.0	7.2		8.3	9.4
ROIC (%)	8.1	7.1	7.8		10.1	12.4

Source: www.clsa.com

Find CLSA research on Bloomberg, Thomson Reuters, FactSet and CapitalIQ - and profit from our evalu@tor proprietary database at clsa.com



Efficiency improved

FY23 results summary

Revenue: FY23 Revenue down by -14.4% YoY to Rmb17,117m (Rmb20,005m in FY22). This missed consensus and our forecasts by -12.0%/-8.5%.

Gross profit and GPM: Gross profit was recorded at Rmb4,003m, representing a decline of -13.0% YoY from Rmb4,600m in FY22. However, GPM improved, increasing by 40bps to 23.4%, this beat consensus forecast of GPM at 23.0% (beat by 40bps), but a miss to our forecasts by 80bps. The improved GPM was mainly due to the company's continuous adjustments on business structure to focus on the new business expansion, while ceased some low-GPM business. Management also mentioned that they improved the efficiency on project delivery in FY23.

Core operating profit (gross profit - S&M expenses - R&D expenses - admin expenses) and Core OPM: Core operating profit decreased from Rmb731m in FY22 to Rmb702m in FY23, representing a decline of -4.0% YoY. Core OPM was up by +0.4% from 3.7% to 4.1%, as CSI conducted strict cost controls.

Net profit and NPM: Net profit attributable to the shareholders in FY23 recorded at Rmb713m, down by -6.1% YoY from Rmb759m in FY22. The NPM increased from 3.8% to 4.2%. CL forecasted FY23 net profit at Rmb833m; while consensus forecasted of Rmb929m. A miss to our and consensus forecasts by -14.3% and -23.2%, respectively.

Dividend: The Company declared the distribution of a final dividend of HK\$0.0811 per share for FY23, representing a payout of around 31.3% (21.7% for FY22).

Figure 1

Revenue summary, by customer							
(Rmbm)	FY20A	FY21A	FY22A	FY23A	FY24CL	FY25CL	FY26CL
Huawei	8,030	9,882	9,827	7,731	7,885	8,280	8,611
Growth (%)		23.1	(0.6)	(21.3)	2.0	5.0	4.0
Contribution (%)	56.9	53.7	49.1	45.2	41.8	38.8	36.2
HSBC	830	1,181	1,159	790	750	713	699
Growth (%)		42.2	(1.9)	(31.8)	(5.0)	(5.0)	(2.0)
Contribution (%)	5.9	6.4	5.8	4.6	4.0	3.3	2.9
Tencent	500	706	697	480	480	490	500
Growth (%)		41.2	(1.3)	(31.1)	-	2.0	2.0
Contribution (%)	3.5	3.8	3.5	2.8	2.5	2.3	2.1
Alibaba	400	597	467	448	448	457	466
Growth (%)		49.2	(21.7)	(4.2)	-	2.0	2.0
Contribution (%)	2.8	3.2	2.3	2.6	2.4	2.1	2.0
Ping An	450	523	490	345	363	388	411
Growth (%)		16.1	(6.3)	(29.4)	5.0	7.0	6.0
Contribution (%)	3.2	2.8	2.4	2.0	1.9	1.8	1.7
Others	3,891	5,510	7,366	7,323	8,952	11,015	13,096
Growth (%)		41.6	33.7	(0.6)	22.2	23.0	18.9
Contribution (%)	27.6	29.9	36.8	42.8	47.4	51.6	55.1
Total revenue	14,101	18,398	20,005	17,117	18,878	21,342	23,782
Growth (%)	17.1	30.5	8.7	(14.4)	10.3	13.0	11.4

Source: CLSA, Company




Figure 2

Revenue summary, by business group											
(Rmbm)	FY20A	FY21A	FY22H1	FY22H2	FY22A	FY23H1	FY23H2	FY23A	FY24CL	FY25CL	FY26CL
Cloud Intelligence Group - CIG	3,243	5,299	3,212	3,406	6,618	3,304	3,146	6,450	7,998	9,918	11,901
Growth (%)	58.4	63.4	50.8	7.5	24.9	2.9	(7.6)	(2.5)	24.0	24.0	20.0
Proportion (%)	23.0	28.8	32.0	34.1	33.1	39.1	36.3	37.7	42.4	46.5	50.0
Traditional business (IT outsourcing)	10,858	13,099	6,813	6,574	13,387	5,146	5,521	10,667	10,880	11,424	11,881
Growth (%)	8.6	20.6	9.7	(4.6)	2.2	(24.5)	(16.0)	(20.3)	2.0	5.0	4.0
Proportion (%)	77.0	71.2	68.0	65.9	66.9	60.9	63.7	62.3	57.6	53.5	50.0
Total revenue	14,101	18,398	10,025	9,980	20,005	8,450	8,667	17,117	18,878	21,342	23,782
Growth (%)	17.1	30.5	20.2	(0.8)	8.7	(15.7)	(13.2)	(14.4)	10.3	13.0	11.4

Source: CLSA, Company

Figure 3



Source: CLSA, Company

Figure 4

Financial summary							
(Rmbm)	FY20A	FY21A	FY22A	FY23CL	FY24CL	FY25CL	FY26CL
Revenue	14,101	18,398	20,005	17,117	18,878	21,342	23,782
Growth (%)	17.1	30.5	8.7	(14.4)	10.3	13.0	11.4
Gross profit	4,118	4,904	4,600	4,003	4,509	5,205	5,919
Growth (%)	14.9	19.1	(6.2)	(13.0)	12.6	15.4	13.7
Margin (%)	29.2	26.7	23.0	23.4	23.9	24.4	24.9
Core operating profit	1,157	956	731	702	897	1,184	1,510
Growth (%)	20.4	(17.4)	(23.6)	(4.0)	27.8	32.1	27.5
Margin (%)	8.2	5.2	3.7	4.1	4.7	5.5	6.3
Operating profit	1,113	908	675	596	791	1,079	1,404
Growth (%)	23.4	(18.4)	(25.6)	(11.8)	32.7	36.4	30.2
Margin (%)	7.9	4.9	3.4	3.5	4.2	5.1	5.9
Net profit	948	1,137	759	713	886	1,107	1,387
Growth (%)	25.3	19.9	(33.2)	(6.1)	24.3	24.9	25.3
Margin (%)	6.7	6.2	3.8	4.2	4.7	5.2	5.8
Net profit attributable to ordinary shareholders	955	1,137	759	713	884	1,104	1,384
Growth (%)	26.5	19.1	(33.2)	(6.1)	24.0	24.9	25.3
Margin (%)	6.8	6.2	3.8	4.2	4.7	5.2	5.8

Source: CLSA, Company

Figure 5

Forecast changes									
Rmbm	NEW			OLD			% change or ppt change		
	FY24CL	FY25CL	FY26CL	FY24CL	FY25CL	FY26CL	FY24CL	FY25CL	FY26CL
Revenue	18,878	21,342	23,782	21,545	24,587	na	(12.4%)	(13.2%)	na
Growth (%)	10.3	13.0	11.4	15.1	14.1	na			
Gross profit	4,509	5,205	5,919	5,385	6,342	na	(16.3%)	(17.9%)	na
Growth (%)	12.6	15.4	13.7	18.9	17.8	na			
Margin (%)	23.9	24.4	24.9	25.0	25.8	na	(1.1)	(1.4)	na
Operating profit	791	1,079	1,404	1,203	1,600	na	(34.3%)	(32.6%)	na
Growth (%)	32.7	36.4	30.2	38.1	33.0	na			
Margin (%)	4.2	5.1	5.9	5.6	6.5	na	(1.4)	(1.5)	na
Net profit	886	1,107	1,387	1,099	1,432	na	(19.4%)	(22.7%)	na
Growth (%)	24.3	24.9	25.3	31.7	30.2	na			
Margin (%)	4.7	5.2	5.8	5.1	5.8	na	(0.4)	(0.6)	na
Net profit attributable to ordinary shareholders	884	1,104	1,384	1,097	1,429	na	(19.4%)	(22.7%)	na
Growth (%)	24.0	24.9	25.3	31.7	30.2	na			
Margin (%)	4.7	5.2	5.8	5.1	5.8	na	(0.4)	(0.6)	na

Source: CLSA, Company

Our net profit forecast changes are mainly due to (1) Slower revenue growth estimations due to prolonged uncertainties on macro economy; (2) Tad lower GPM expectations and (3) Lower expectations on operating leverage from the top-line.

Figure 6



Dated: 30 Mar 2024. Source: CLSA, Refinitiv

Figure 7

Chinasoft International: target price computation - new	
	25CL
25CL Net profit attributable to equity shareholders (Rmbm)	1,104
Target PE multiple (x)	14.5
Equity value (Rmbm)	16,015
Number of shares - diluted (m)	2,847
Exchange ratio (Rmb/HK\$)	1.11
Target price (HK\$), rounding	6.30

Source: CLSA

Figure 8

Chinasoft International: target price computation - old: 9 Jan 2024

	25CL
25CL Net profit attributable to equity shareholders (Rmbm)	1,429
Target PE multiple (x)	14.5
Equity value (Rmbm)	20,717
Number of shares - diluted (m)	3,006
Exchange ratio (Rmb/HK\$)	1.11
Target price (HK\$), rounding	7.70

Source: CLSA

Figure 9

Peer comp table for CSI

Company	Ticker	Last price (local ccy)	Mkt Cap (US\$m)	3M ADTO (US\$m)	PE 24 (x)	PE 25 (x)	EV/Sales 24 (x)	EV/Sales 25 (x)	EV/EBITDA 24 (x)	EV/EBITDA 25 (x)
CSI	0354.HK	4.72	1,753	16.0	14.0	11.2	0.5	0.5	7.4	6.1
Digital China	000034.SZ	29.52	2,735	108.9	13.5	11.3	0.3	0.3	14.3	12.5
GIE Consulting	300687.SZ	18.40	1,044	25.8	20.1	15.3	2.2	1.7	17.9	13.9
AsiaInfo	1675.HK	7.17	857	1.4	6.6	6.0	0.4	0.4	3.1	2.7
iSoftstone	301236.SZ	46.48	6,134	406.3	29.9	22.6	1.7	1.4	20.8	15.9
Accenture	ACN.N	346.61	232,375	252.5	28.6	26.4	3.5	3.3	18.8	17.1
IBM	IBM	190.96	175,062	960.3	18.9	17.9	3.4	3.3	13.6	13.2
Infosys	INFY.NS	1,498.05	74,446	130.5	25.2	22.4	3.4	3.3	13.6	13.2
TATA Consultancy	TCS.NS	3,876.30	168,377	118.4	30.6	27.5	5.6	5.2	21.3	19.1
Average					20.8	17.8	2.3	2.1	14.5	12.6

Dated: 30 Mar 2024. Source: CLSA, Refinitiv

Investment thesis

Chinasoft Intl recently is experiencing an uneasy time amid a weak economy in China. The demand for traditional IT outsourcing business from key clients have been slowing down. This was, however, slightly offset by telecommunication companies and some SOE demand as well as the modest growth of cloud intelligence group (CIG) segment. That said, the company will control costs (by downsizing staff, etc.) in a stricter manner to account for this environment, and hence to improve margin. As the only few Huawei-related stocks in H-share, we expect it to be benefit with Huawei's continue expansion to its software ecosystem.

Catalysts

CSI has multiple relationships with Huawei, including cross-selling of Huawei Cloud and Huawei all-in-one AI server; and implementation of MetaERP, OpenHarmony IoT projects etc.; and it also leveraging Huawei's AI-related capabilities to launched an AI application platform to provide solutions for different industries. Any breakthrough or further investment from Huawei onto these areas could potentially benefit to Chinasoft Intl'.

Valuation details

Our target price is based on 14.5x 25CL PE, largely in line with the company's 10-year historical forward trading average PE. Our target PE multiple reflects the H-share investment sentiment and increasing investor interest in the Huawei-related theme.

Investment risks

We believe the primary investment risks come from 1) uncertainties on Huawei; 2) uncertainties from new products/services development; 3) risk of greater competition; 4) risk of economic downturn; and 5) risk from Covid-19 pandemic that delays delivery of services.

Detailed financials

Profit & Loss (Rmbm)

Year to 31 December	2020A	2021A	2022A	2023A	2024CL	2025CL	2026CL
Revenue	14,101	18,398	20,005	17,117	18,878	21,342	23,782
Cogs (ex-D&A)	(9,654)	(13,050)	(14,905)	(12,688)	(14,069)	(15,886)	(17,643)
Gross Profit (ex-D&A)	4,448	5,348	5,100	4,429	4,809	5,455	6,140
Research & development costs	(930)	(1,249)	(1,238)	(1,078)	(1,180)	(1,312)	(1,439)
Selling & marketing expenses	(729)	(943)	(949)	(868)	(948)	(1,051)	(1,147)
Other SG&A	(1,302)	(1,756)	(1,683)	(1,355)	(1,485)	(1,657)	(1,823)
Other Op Expenses ex-D&A	-	-	-	-	-	-	-
Op Ebitda	1,486	1,400	1,230	1,127	1,196	1,435	1,731
Depreciation/amortisation	(329)	(444)	(500)	(426)	(300)	(251)	(221)
Op Ebit	1,157	956	731	702	897	1,184	1,510
Interest income	76	0	0	0	0	0	0
Interest expense	(151)	(100)	(113)	(203)	(190)	(181)	(172)
Net interest inc/(exp)	(76)	(100)	(113)	(203)	(190)	(181)	(172)
Associates/investments	-	-	-	-	-	-	-
Forex/other income	-	-	-	-	-	-	-
Asset sales/other cash items	237	419	348	429	399	339	305
Provisions/other non-cash items	(283)	(23)	(135)	(194)	(154)	(154)	(154)
Asset revaluation/Exceptional items	-	-	-	-	-	-	-
Profit before tax	1,035	1,252	830	734	952	1,189	1,490
Taxation	(87)	(115)	(71)	(21)	(66)	(82)	(103)
Profit after tax	948	1,137	759	713	886	1,107	1,387
Preference dividends	-	-	-	-	-	-	-
Profit for period	948	1,137	759	713	886	1,107	1,387
Minority interest	7	0	1	1	(2)	(2)	(3)
Net profit	955	1,137	759	713	884	1,104	1,384
Extraordinaries/others	0	0	0	0	0	0	0
Profit available to ordinary shares	955	1,137	759	713	884	1,104	1,384
Dividends	(52)	(70)	(80)	(138)	(177)	(221)	(277)
Retained profit	903	1,067	680	575	707	884	1,107
Adjusted profit	955	1,137	759	713	884	1,104	1,384
EPS (Rmb)	0.3	0.4	0.3	0.3	0.3	0.4	0.5
Adj EPS [pre excep] (Rmb)	0.3	0.4	0.3	0.3	0.3	0.4	0.5
Core EPS (Rmb)	0.3	0.4	0.3	0.3	0.3	0.4	0.5
DPS (Rmb)	0.0	0.0	0.0	0.1	0.1	0.1	0.1

Profit & loss ratios

Year to 31 December	2020A	2021A	2022A	2023A	2024CL	2025CL	2026CL
Growth (%)							
Revenue growth (% YoY)	17.1	30.5	8.7	(14.4)	10.3	13.0	11.4
Ebitda growth (% YoY)	17.6	(5.8)	(12.1)	(8.4)	6.1	20.0	20.6
Ebit growth (% YoY)	20.4	(17.4)	(23.6)	(4.0)	27.8	32.1	27.5
Net profit growth (%)	26.5	19.1	(33.2)	(6.1)	24.0	24.9	25.3
EPS growth (% YoY)	20.6	12.5	(34.4)	(0.5)	24.0	24.9	25.3
Adj EPS growth (% YoY)	20.6	12.5	(34.4)	(0.5)	24.0	24.9	25.3
DPS growth (% YoY)	32.4	(22.0)	8.5	83.5	27.8	24.9	25.3
Core EPS growth (% YoY)	20.6	12.5	(34.4)	(0.5)	24.0	24.9	25.3
Margins (%)							
Gross margin (%)	31.5	29.1	25.5	25.9	25.5	25.6	25.8
Ebitda margin (%)	10.5	7.6	6.2	6.6	6.3	6.7	7.3
Ebit margin (%)	8.2	5.2	3.7	4.1	4.7	5.5	6.3
Net profit margin (%)	6.8	6.2	3.8	4.2	4.7	5.2	5.8
Core profit margin	6.8	6.2	3.8	4.2	4.7	5.2	5.8
Op cashflow margin	8.2	5.2	3.8	2.3	6.1	5.2	5.8
Returns (%)							
ROE (%)	12.5	11.2	6.4	6.0	7.2	8.3	9.4
ROA (%)	8.9	5.8	3.9	4.0	4.7	5.8	6.8
ROIC (%)	16.2	11.9	8.1	7.1	7.8	10.1	12.4
ROCE (%)	17.5	12.9	8.6	7.0	8.1	10.5	12.9
Other key ratios (%)							
Effective tax rate (%)	8.4	9.2	8.6	2.9	6.9	6.9	6.9
Ebitda/net int exp (x)	19.6	14.1	10.9	5.6	6.3	7.9	10.1
Exceptional or extraord. inc/PBT (%)	-	-	-	-	-	-	-
Dividend payout (%)	9.5	6.6	10.9	20.0	20.7	20.7	20.7

Source: www.clsa.com



Balance sheet (Rmbm)

Year to 31 December	2020A	2021A	2022A	2023A	2024CL	2025CL	2026CL
Cash & equivalents	3,787	5,556	5,005	3,788	4,676	5,493	6,659
Accounts receivable	4,580	5,894	6,157	6,092	6,272	6,648	7,077
Inventories	51	163	99	96	106	120	134
Other current assets	1,976	1,906	2,339	2,969	3,192	3,504	3,645
Current assets	10,394	13,520	13,601	12,945	14,246	15,765	17,515
Fixed assets	858	1,220	1,119	1,151	1,149	1,105	1,018
Investments	247	385	485	429	429	429	429
Goodwill	941	844	844	844	844	844	844
Other intangible assets	145	193	281	336	373	453	526
Other non-current assets	502	741	636	1,363	1,221	1,156	1,115
Total assets	13,087	16,902	16,965	17,068	18,262	19,751	21,446
Short term loans/OD	368	917	766	735	735	735	735
Accounts payable	1,753	2,252	2,043	1,663	1,822	2,046	2,195
Accrued expenses	-	-	-	-	-	-	-
Taxes payable	83	181	154	163	163	163	163
Other current liabs	514	636	590	402	437	480	525
Current liabilities	2,718	3,986	3,553	2,962	3,156	3,424	3,617
Long-term debt/leases/other	1,421	1,021	1,162	2,282	2,282	2,282	2,282
Convertible bonds	0	0	0	0	0	0	0
Provisions/other LT liabs	171	269	114	57	57	57	57
Total liabilities	4,311	5,276	4,830	5,301	5,495	5,763	5,956
Share capital	4,867	6,432	6,151	5,608	5,608	5,608	5,608
Retained earnings	4,492	5,760	6,498	7,249	8,248	9,467	10,965
Reserves/others	(605)	(589)	(539)	(1,114)	(1,114)	(1,114)	(1,114)
Shareholder funds	8,753	11,604	12,110	11,742	12,741	13,960	15,459
Minorities/other equity	23	23	25	24	26	28	31
Total equity	8,776	11,627	12,135	11,767	12,767	13,989	15,490
Total liabs & equity	13,087	16,902	16,965	17,068	18,263	19,751	21,446
Total debt	1,790	1,938	1,929	3,017	3,017	3,017	3,017
Net debt	(1,997)	(3,618)	(3,077)	(771)	(1,659)	(2,476)	(3,642)
Adjusted EV	9,520	7,611	8,723	11,227	10,340	9,526	8,363
BVPS (Rmb)	3.1	3.9	4.0	4.1	4.5	4.9	5.4

Balance sheet ratios

Year to 31 December	2020A	2021A	2022A	2023A	2024CL	2025CL	2026CL
Key ratios							
Current ratio (x)	3.8	3.4	3.8	4.4	4.5	4.6	4.8
Growth in total assets (% YoY)	21.8	29.2	0.4	0.6	7.0	8.2	8.6
Growth in capital employed (% YoY)	5.0	18.1	13.1	21.4	1.0	3.6	2.9
Net debt to operating cashflow (x)	-	-	-	-	-	-	-
Gross debt to operating cashflow (x)	1.6	2.0	2.5	7.8	2.6	2.7	2.2
Gross debt to Ebitda (x)	1.2	1.4	1.6	2.7	2.5	2.1	1.7
Net debt/Ebitda (x)	-	-	-	-	-	-	-
Gearing							
Net debt/equity (%)	(22.8)	(31.1)	(25.4)	(6.6)	(13.0)	(17.7)	(23.5)
Gross debt/equity (%)	20.4	16.7	15.9	25.6	23.6	21.6	19.5
Interest cover (x)	8.1	9.6	6.5	3.5	4.7	6.6	8.8
Debt cover (x)	0.6	0.5	0.4	0.1	0.4	0.4	0.5
Net cash per share (Rmb)	0.7	1.2	1.0	0.3	0.6	0.9	1.3
Working capital analysis							
Inventory days	1.9	2.9	3.1	2.7	2.6	2.6	2.6
Debtor days	102.0	103.9	109.9	130.6	119.5	110.5	105.3
Creditor days	54.5	54.2	50.9	51.6	44.3	43.7	43.3
Working capital/Sales (%)	30.2	26.6	29.0	40.5	37.9	35.5	33.5
Capital employed analysis							
Sales/Capital employed (%)	208.0	229.7	220.9	155.7	170.0	185.4	200.7
EV/Capital employed (%)	140.4	95.0	96.3	102.1	93.1	82.7	70.6
Working capital/Capital employed (%)	62.8	61.1	64.1	63.0	64.4	65.9	67.3
Fixed capital/Capital employed (%)	12.7	15.2	12.4	10.5	10.3	9.6	8.6
Other ratios (%)							
PB (x)	1.3	1.0	1.0	1.1	1.0	0.9	0.8
EV/Ebitda (x)	6.4	5.4	7.1	10.0	8.6	6.6	4.8
EV/OCF (x)	8.3	7.9	11.4	29.0	8.9	8.6	6.0
EV/FCF (x)	9.6	14.8	15.6	(1,933.0)	10.7	10.8	6.8
EV/Sales (x)	0.7	0.4	0.4	0.7	0.5	0.4	0.4
Capex/depreciation (%)	57.0	113.2	45.9	123.0	81.9	121.2	112.2

Source: www.clsa.com

Cashflow (Rmbm)

Year to 31 December	2020A	2021A	2022A	2023A	2024CL	2025CL	2026CL
Operating profit	1,157	956	731	702	897	1,184	1,510
Operating adjustments	(122)	296	99	32	55	4	(20)
Depreciation/amortisation	329	444	500	426	300	251	221
Working capital changes	(533)	(887)	(683)	(1,109)	(219)	(434)	(391)
Interest paid / other financial expenses	-	-	-	-	-	-	-
Tax paid	(83)	(20)	(97)	(15)	(66)	(82)	(103)
Other non-cash operating items	405	173	216	353	190	181	172
Net operating cashflow	1,153	962	765	388	1,157	1,104	1,389
Capital expenditure	(163)	(449)	(204)	(394)	(193)	(221)	(166)
Free cashflow	990	513	561	(6)	964	883	1,223
Acq/inv/disposals	(98)	(50)	(165)	(327)	179	-	-
Int, invt & associate div	69	(30)	(281)	507	(179)	-	-
Net investing cashflow	(192)	(530)	(650)	(214)	(193)	(221)	(166)
Increase in loans	217	173	(101)	(31)	0	0	0
Dividends	(52)	(70)	(80)	0	0	0	0
Net equity raised/others	196	1,274	(601)	(1,474)	(190)	(181)	(172)
Net financing cashflow	362	1,377	(781)	(1,505)	(190)	(181)	(172)
Incr/(decr) in net cash	1,323	1,810	(666)	(1,332)	774	702	1,051
Exch rate movements	(62)	(40)	114	114	114	114	114
Opening cash	2,526	3,787	5,556	5,005	3,788	4,676	5,493
Closing cash	3,787	5,556	5,005	3,788	4,676	5,493	6,659
OCF PS (Rmb)	0.4	0.3	0.3	0.1	0.4	0.4	0.5
FCF PS (Rmb)	0.4	0.2	0.2	0.0	0.3	0.3	0.4

Cashflow ratio analysis

Year to 31 December	2020A	2021A	2022A	2023A	2024CL	2025CL	2026CL
Growth (%)							
Op cashflow growth (% YoY)	52.8	(16.5)	(20.5)	(49.3)	198.4	(4.6)	25.8
FCF growth (% YoY)	52.9	(48.1)	9.3	(101.0)	-	(8.4)	38.5
Capex growth (%)	52.2	175.7	(54.6)	92.9	(50.9)	14.5	(25.1)
Other key ratios (%)							
Capex/sales (%)	1.2	2.4	1.0	2.3	1.0	1.0	0.7
Capex/op cashflow (%)	14.1	46.7	26.7	101.5	16.7	20.0	11.9
Operating cashflow payout ratio (%)	7.8	7.8	10.8	36.8	15.8	20.7	20.6
Cashflow payout ratio (%)	4.5	7.3	10.4	35.7	15.3	20.0	19.9
Free cashflow payout ratio (%)	5.2	13.7	14.2	-	18.4	25.0	22.6

DuPont analysis

Year to 31 December	2020A	2021A	2022A	2023A	2024CL	2025CL	2026CL
Ebit margin (%)	8.2	5.2	3.7	4.1	4.7	5.5	6.3
Asset turnover (x)	1.2	1.2	1.2	1.0	1.1	1.1	1.2
Interest burden (x)	0.9	1.3	1.1	1.0	1.1	1.0	1.0
Tax burden (x)	0.9	0.9	0.9	1.0	0.9	0.9	0.9
Return on assets (%)	8.9	5.8	3.9	4.0	4.7	5.8	6.8
Leverage (x)	1.6	1.5	1.4	1.4	1.4	1.4	1.4
ROE (%)	12.5	11.2	6.4	6.0	7.2	8.3	9.4

EVA® analysis

Year to 31 December	2020A	2021A	2022A	2023A	2024CL	2025CL	2026CL
Ebit adj for tax	1,060	868	668	681	835	1,103	1,406
Average invested capital	6,534	7,298	8,290	9,655	10,679	10,938	11,308
ROIC (%)	16.2	11.9	8.1	7.1	7.8	10.1	12.4
Cost of equity (%)	12.4	12.4	12.4	12.4	12.4	12.4	12.4
Cost of debt (adj for tax)	3.7	3.6	3.7	3.9	3.7	3.7	3.7
Weighted average cost of capital (%)	11.6	11.6	11.6	11.6	11.6	11.6	11.6
EVA/IC (%)	4.6	0.3	(3.5)	(4.6)	(3.8)	(1.5)	0.8
EVA (Rmbm)	302	21	(294)	(441)	(405)	(167)	93

Source: www.clsa.com



Research subscriptions

To change your report distribution requirements, please contact your CLSA sales representative or email us at cib@clsa.com. You can also fine-tune your Research Alert email preferences at https://www.clsa.com/member/tools/email_alert/.

Companies mentioned


- Chinasoft Intl (354 HK - HK\$4.72 - BUY)
- Accenture (N-R)
- Accenture (N-R)
- AsiaInfo (N-R)
- Digital China (N-R)
- GIE Consulting (N-R)
- HSBC (N-R)
- Huawei Tech (N-R)
- IBM (N-R)
- Infosys (INFO IB - RS1,498.8 - O-PF)
- iSoftStone (N-R)
- Tata Consultancy (TCS IB - RS3,883.6 - SELL)
- Tencent (700 HK - HK\$303.80 - BUY)

Analyst certification

The analyst(s) of this report hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this research report.

Important disclosures

Recommendation history of Chinasoft International Ltd. 354 HK




Date	Rec	Target	Date	Rec	Target
LATEST	BUY	6.30	02 Mar 2023	BUY	7.70
09 Jan 2024	BUY	7.70	07 Jan 2023	BUY	9.00
21 Aug 2023	O-PF	5.70	31 Aug 2022	BUY	8.50
30 Mar 2023	BUY	6.70	28 Apr 2022	BUY	10.00

Source: CLSA

Click to rate this research




Recommendation history of Tata Consultancy Services Ltd TCS IB



Date	Rec	Target	Date	Rec	Target
05 Mar 2024	SELL	3,925.00	07 Mar 2022	O-PF	3,850.00
15 Jan 2024	U-PF	3,925.00	13 Jan 2022	O-PF	4,200.00
10 Jan 2023	O-PF	3,550.00	03 Jan 2022	O-PF	4,170.00
02 Jan 2023	O-PF	3,500.00	21 Sep 2021	O-PF	4,050.00
02 Oct 2022	O-PF	3,450.00	01 Jul 2021	O-PF	3,770.00
01 Jul 2022	O-PF	3,750.00	13 Apr 2021	O-PF	3,560.00
07 Jun 2022	O-PF	3,760.00	01 Apr 2021	O-PF	3,370.00
12 Apr 2022	O-PF	4,000.00			

Source: CLSA


Recommendation history of Tencent Holdings Ltd 700 HK



Date	Rec	Target	Date	Rec	Target
25 Jan 2024	BUY	440.00	24 Mar 2022	BUY	665.00*
17 Feb 2023	BUY	500.00	27 Jan 2022	BUY	780.00*
09 Nov 2022	BUY	450.00*	19 Aug 2021	BUY	757.07*
29 Sep 2022	BUY	500.00*	31 Jul 2021	BUY	801.72*
21 Jul 2022	BUY	575.00*	21 May 2021	BUY	829.86*
12 May 2022	BUY	600.00*			

Source: CLSA; * Adjusted for corporate action

Recommendation history of Infosys Ltd INFO IB



Date	Rec	Target	Date	Rec	Target
15 Jan 2024	O-PF	1,741.00	13 Jan 2022	BUY	2,280.00
14 Apr 2023	O-PF	1,550.00	03 Jan 2022	BUY	2,250.00
14 Oct 2022	BUY	1,800.00	14 Oct 2021	BUY	2,060.00
01 Jul 2022	BUY	1,750.00	21 Sep 2021	BUY	2,000.00
07 Jun 2022	BUY	1,800.00	01 Jul 2021	BUY	1,900.00
07 Mar 2022	BUY	2,040.00	01 Apr 2021	BUY	1,660.00

Source: CLSA

CLSA ("CLSA") in this report refers to CLSA Limited, CLSA Americas, LLC, CLSA Australia Pty Ltd, CLSA India Private Limited, PT CLSA Sekuritas Indonesia, CLSA Securities Japan Co., Ltd., CLSA Securities Korea Ltd., CLSA Securities Malaysia Sdn. Bhd., CLSA Philippines, Inc, CLSA Singapore Pte Ltd, CLSA Securities (Thailand) Limited, CLSA (UK), CLSA Europe B.V. and/or their respective affiliates. CLST ("CLST") in this report refers to CL Securities Taiwan Co., Ltd.

The policies of CLSA and CLST are to only publish research that is impartial, independent, clear, fair, and not misleading. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to a research report as below. This research disclosure should be read in conjunction with the research disclaimer as set out hereof and at www.clsa.com/disclaimer.html, the Terms and Conditions of Use as set out at <https://www.clsa.com/terms-and-conditions-of-use/> and the applicable regulation of the concerned market where the analyst is stationed and hence subject to. Investors are strongly encouraged to review this disclaimer before investing.

Neither analysts nor their household members or associates may have a financial interest in, or be an officer, director or advisory board member of companies covered by the analyst unless disclosed herein. In circumstances where an analyst has a pre-existing holding in any securities under coverage, those holdings are grandfathered and the analyst is prohibited from trading such securities.

The analysts included herein hereby confirm that they have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts attest that they were not in possession of any material, non-public information regarding the subject company that has securities listed in the relevant jurisdiction(s) at the time of publication of this report. (For full disclosure of interest for all companies covered by CLSA in this report, please refer to http://www.clsa.com/member/research_disclosures/ for details.)

As analyst(s) of this report, I/we hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this report or to any investment banking relationship with the subject company covered in this report (for the past one year) or otherwise

any other relationship with such company which leads to receipt of fees from the company except in ordinary course of business of the company. The analyst/s also state/s and confirm/s that he/she/they has/have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts included herein attest that they were not in possession of any material, non-public information regarding the subject company that has securities listed in the relevant jurisdiction(s) at the time of publication of this report. The analysts further confirm that none of the information used in this report was received from CLSA's Corporate Finance department or CLSA's and/or CLST's Sales and Trading business. Save from the disclosure below (if any), the analyst(s) is/are not aware of any material conflict of interest.

The research analyst(s) or his/her household member(s)/associate(s) or any employee of CLSA and/or CLST who has the ability to influence research or a member of his/her household has/have a financial interest in the securities or related securities of Tata Consultancy Services Ltd.

The research analyst(s) or his/her household member(s)/associate(s) or any employee of CLSA and/or CLST who has the ability to influence research or a member of his/her household has/have a financial interest in the securities or related securities of Infosys Ltd.

For the companies under research coverage, CLSA and/or CLST expect(s) to receive or intend(s) to seek compensation for investment banking services from Tencent Holdings Ltd in the next three months.

CLSA and/or CLST (and/or their respective affiliates) make a market in the securities of the following listed corporations.

Key to CLSA/CLST investment rankings: BUY: Total stock return (including dividends) expected to exceed 20%; O-PF (aka ACCUMULATE): Total expected return below 20% but exceeding market return; U-PF (aka REDUCE): Total expected return positive but below market return; SELL: Total return expected to be negative. For relative performance, we benchmark the 12-month total forecast return (including dividends) for the stock against the 12-month forecast return (including dividends) for the market on which the stock trades.

"High Conviction" Ideas are not necessarily stocks with the most upside/downside, but those where the Research Head/Strategist believes there is the highest likelihood of positive/negative returns.

The list for each market is monitored weekly.

Overall rating distribution for CLSA (exclude CLST) only Universe: Overall rating distribution: BUY / Outperform - CLSA: 73.73%, Underperform / SELL - CLSA: 26.27%, Restricted - CLSA: 0.24%; Data as of 1 Jan 2024. Investment banking clients as a % of rating category: BUY / Outperform - CLSA: 13.25%, Underperform / SELL - CLSA: 2.89%; Restricted - CLSA: 0.24%. Data for 12-month period ending 1 Jan 2024.

Overall rating distribution for CLST only Universe: Overall rating distribution: BUY / Outperform - CLST: 67.86%, Underperform / SELL - CLST: 32.14%, Restricted - CLST: 0.00%. Data as of 1 Jan 2024. Investment banking clients as a % of rating category: BUY / Outperform - CLST: 0.00%, Underperform / SELL - CLST: 0.00%, Restricted - CLST: 0.00%. Data for 12-month period ending 1 Jan 2024.

There are no numbers for Hold/Neutral as CLSA/CLST do not have such investment rankings. For a history of the recommendation, price targets and disclosure information for companies mentioned in this report please write to: CLSA Group Compliance, 18/F, One Pacific Place, 88 Queensway, Hong Kong and/or; CLST Compliance (27/F, 95, Section 2 Dun Hua South Road, Taipei 10682, Taiwan, telephone (886) 2 2326 8188). EVA® is a registered trademark of Stern, Stewart & Co. "CL" in charts and tables stands for CLSA estimates, "CT" stands for CLST estimates, "CRR" stands for CRR Research estimates and "CS" for Citic Securities estimates unless otherwise noted in the source.

Charts and tables sourced to CLSA in this report may include data extracted from CLSA's automated databases, which derive their original data from a range of sources. These can include: companies; analyst estimates/calculations; local exchanges and/or third-party data or market pricing providers such as Bloomberg, FactSet or IBES. Additional information on data sources for specific charts or tables can be obtained by contacting the publishing analysts.

This report is subject to and incorporates the terms and conditions of use set out on the www.clsa.com website (<https://www.clsa.com/disclaimer.html> and <https://www.clsa.com/terms-and-conditions-of-use/>) and the references to "publication/communication" or "Publications" thereof shall include this report. Neither this report nor any portion hereof may be reprinted, sold, resold, copied, reproduced, distributed, redistributed, published, republished, displayed, posted or transmitted in any form or media or by any means without the written consent of CLSA and/or CLST. CLSA and/or CLST has/have produced this report for private circulation to professional, institutional and/or wholesale clients only, and may not be distributed to retail investors. The information, opinions and estimates herein are not directed at, or intended for distribution to or use by, any person or entity in any jurisdiction where doing so would be contrary to law or regulation or which would subject CLSA and/or CLST to any additional registration or licensing requirement within such jurisdiction. The information and statistical data (for private or public companies) herein have been obtained from sources we believe to be reliable. Such information has not been independently verified and CLSA and/or CLST makes no representation or warranty as to its fairness, adequacy, accuracy, completeness or correctness. The replication of any third party views in this report should not be treated necessarily as an indication that CLSA and/or CLST agrees with or concurs with such views. None of CLSA and/or CLST, its affiliates and their respective directors, officers, employees, advisers and representatives makes any representation or warranty, express or implied, as to and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such data or information contained herein or any statement made in this report. Any opinions or estimates herein reflect the judgment of CLSA and/or CLST at the date of this report and are subject to change at any time without notice. Where any part of the information, opinions or estimates contained herein reflects the views and opinions of a sales person or a non-analyst, such views and opinions may not correspond to the published view of CLSA and/or CLST. Any price target given in the report may be projected from one or more valuation models and hence any price target may be subject to the inherent risk of the selected model as well as other external risk factors. Where the publication does not contain ratings, the material should not be construed as research but is offered as factual commentary. It is not intended to, nor should it be used to form an

investment opinion about the non-rated companies.

This report is for information purposes only and it does not constitute or contain, and should not be considered as an offer or invitation to sell, or any solicitation or invitation of any offer to subscribe for or purchase any securities in any jurisdiction and recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. This is not intended to provide professional, investment or any other type of advice or recommendation and does not take into account the particular investment objectives, financial situation or needs of individual recipients. Before acting on any information in this report, you should consider whether it is suitable for your particular circumstances and, if appropriate, seek professional advice, including legal or tax advice. Investments involve risks, and investors should exercise prudence and their own judgment in making their investment decisions. The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Investments that are denominated in foreign currencies may fluctuate in value as a result of exposure to movements of exchange rate. Past performance is not necessarily a guide to future performance or liquidity. CLSA and/or CLST do/does not accept any responsibility and cannot be held liable for any person's use of or reliance on the information and opinions contained herein. To the extent permitted by applicable securities laws and regulations, CLSA and/or CLST accept(s) no liability whatsoever for any direct or consequential loss arising from the use of this report or its contents.

To maintain the independence and integrity of our research, our Corporate Finance, Sales Trading, Asset Management and Research business lines are distinct from one another. This means that CLSA's Research department is not part of and does not report to CLSA's Corporate Finance department or CLSA's Sales and Trading business. Accordingly, neither the Corporate Finance department nor the Sales and Trading department supervises or controls the activities of CLSA's research analysts. CLSA's research analysts report to the management of the Research department, who in turn report to CLSA's senior management. CLSA has put in place a number of internal controls designed to manage conflicts of interest that may arise as a result of CLSA engaging in Corporate Finance, Sales and Trading, Asset Management and Research activities. Some examples of these controls include: the use of information barriers and other controls designed to ensure that confidential information is only shared on a "need to know" basis and in compliance with CLSA's Chinese Wall policies and procedures; measures designed to ensure that interactions that may occur among CLSA's Research personnel, Corporate Finance, Asset Management, and Sales and Trading personnel, CLSA's financial product issuers and CLSA's research analysts do not compromise the integrity and independence of CLSA's research.

Subject to any applicable laws and regulations at any given time, CLSA, CLST, their respective affiliates, officers, directors or employees may have used the information contained herein before publication and may have positions in, or may from time to time purchase or sell or have a material interest in any of the securities mentioned or related securities, or may currently or in future have or have had a business or financial relationship with, or may provide or have provided corporate finance/capital markets and/or other services to, the entities referred to herein, their advisors and/or any other connected parties. As a result, you should be aware that CLSA and/or CLST and/or their respective affiliates, officers, directors or employees may have one or more conflicts of interest. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to research reports. Details of the disclosable interest can be found in certain reports as required by the relevant rules and regulation and the full details of conflict of interest with companies under coverage are available at http://www.clsa.com/member/research_disclosures/. Disclosures therein include the position of CLSA and CLST only. Unless specified otherwise, CLSA did not receive any compensation or other benefits from the subject company, covered in this report, or from any third party. If investors have any difficulty accessing this website, please contact webadmin@clsa.com. If you require disclosure information on previous dates, please contact compliance_hk@clsa.com.

Any disputes related to this report shall be governed by the laws

of Hong Kong and to the non-exclusive jurisdiction of the courts of Hong Kong in connection with any suite, action or proceeding arising out of or in connection with this material. In the event any of the provisions in these Terms of Use shall be held to be unenforceable, that provision shall be enforced to the maximum extent permissible to reflect the intention underlying the unenforceable term, and the remainder of these General Disclaimer shall be unimpaired.

This report is distributed for and on behalf of CLSA (for research compiled by non-US and non-Taiwan analyst(s)), CLSA Americas, LLC (for research compiled by US analyst(s)) and/or CLST (for research compiled by Taiwan analyst(s)) in Australia by CLSA Australia Pty Ltd (ABN 53 139 992 331/AFSL License No: 350159); in Hong Kong by CLSA Limited (Incorporated in Hong Kong with limited liability); in India by CLSA India Private Limited, (Address: 8/F, Dalamal House, Nariman Point, Mumbai 400021. Tel No: +91-22-66505050. Fax No: +91-22-22840271; CIN: U67120MH1994PLC083118; SEBI Registration No: INZ000001735 as Stock Broker, INM000010619 as Merchant Banker and INH000001113 as Research Analyst; in Indonesia by PT CLSA Sekuritas Indonesia; in Japan by CLSA Securities Japan Co., Ltd.; in Korea by CLSA Securities Korea Ltd.; in Malaysia by CLSA Securities Malaysia Sdn. Bhd.; in the Philippines by CLSA Philippines Inc (a member of Philippine Stock Exchange and Securities Investors Protection Fund); in Singapore by CLSA Singapore Pte Ltd and solely to persons who qualify as an "Institutional Investor", "Accredited Investor" or "Expert Investor" MCI (P) 042/11/2022; in Thailand by CLSA Securities (Thailand) Limited; in Taiwan by CLST (for reports compiled by Taiwan analyst(s)) or CLSA (for non Taiwan stock reports to CLSA clients) and in the European Economic Area ("EEA") by CLSA Europe BV and in the United Kingdom by CLSA (UK).

Hong Kong: This research report is distributed by CLSA Limited. This research report is distributed in Hong Kong only to professional investors (as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and any rules promulgated thereunder) and may not be distributed to retail investors. Recipients should contact CLSA Limited, Tel: +852 2600 8888 in respect of any matters arising from, or in connection with, the analysis or report.

Australia: CLSA Australia Pty Ltd ("CAPL") (ABN 53 139 992 331/AFS License No: 350159) is regulated by the Australian Securities and Investments Commission ("ASIC") and is a Market Participant of ASX Limited and Cboe Australia Pty Ltd. This material is issued and distributed by CAPL in Australia to "wholesale clients" only. This material does not take into account the specific investment objectives, financial situation or particular needs of the recipient. The recipient of this material must not distribute it to any third party without the prior written consent of CAPL. For the purposes of this paragraph the term "wholesale client" has the meaning given in section 761G of the Corporations Act 2001. CAPL's research coverage universe spans listed securities across the ASX All Ordinaries index, securities listed on offshore markets, unlisted issuers and investment products which Research management deem to be relevant to the investor base from time to time. CAPL seeks to cover companies of relevance to its domestic and international investor base across a variety of sectors.

India: CLSA India Private Limited, incorporated in November 1994 provides equity brokerage services (SEBI Registration No: INZ000001735), research services (SEBI Registration No: INH000001113) and merchant banking services (SEBI Registration No: INM000010619) to global institutional investors, pension funds and corporates. CLSA and its associates may have debt holdings in the subject company. Further, CLSA and its associates, in the past 12 months, may have received compensation for non-investment banking services and/or non-securities related services from the subject company. For further details of "associates" of CLSA India please contact Compliance-India@clsa.com. Registration granted by SEBI and certification from NISM in no way guarantee performance

of CLSA India Private Limited or provide any assurance of returns to investors. Compliance officer & Grievance officer: Neeta Sanghavi, Tel: 22 6650 5050. Email address of Compliance officer and Grievance cell: compliance-india@clsa.com.

Singapore: This report is distributed in Singapore by CLSA Singapore Pte Ltd to institutional investors, accredited investors or expert investors (each as defined under the Financial Advisers Regulations) only. Singapore recipients should contact CLSA Singapore Pte Ltd, 80 Raffles Place, #18-01, UOB Plaza 1, Singapore 048624, Tel: +65 6416 7888, in respect of any matters arising from, or in connection with, the analysis or report. By virtue of your status as an institutional investor, accredited investor or expert investor, CLSA Singapore Pte Ltd is exempted from complying with certain requirements under the Financial Advisers Act 2001, the Financial Advisers Regulations and the relevant Notices and Guidelines issued thereunder (as disclosed in Part C of the Securities Dealing Services – Singapore Annex of the CLSA terms of business), in respect of any financial advisory services that CLSA Singapore Pte Ltd may provide to you. MCI (P) 042/11/2022.

United States of America: Where any section of the research is compiled by US analyst(s), it is distributed by CLSA Americas, LLC. Where any section is compiled by non-US analyst(s), it is distributed into the United States by CLSA (except CLSA Americas, LLC) solely to persons who qualify as "Major US Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934 and who deal with CLSA Americas, LLC. However, the delivery of this research report to any person in the United States shall not be deemed a recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research in the United States wishing to effect a transaction in any security mentioned herein should do so by contacting CLSA Americas, LLC.

The United Kingdom: This document is a marketing communication. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research, and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The document is disseminated in the UK by CLSA (UK) and directed at persons having professional experience in matters relating to investments, as defined in the relevant applicable local regulations. Any investment activity to which it relates is only available to such persons. If you do not have professional experience in matters relating to investments you should not rely on this document. Where research material is compiled by UK analyst(s), it is produced and disseminated by CLSA (UK). For the purposes of the Financial Conduct Rules in the UK such material is prepared and intended as substantive research material. CLSA (UK) is authorised and regulated by the Financial Conduct Authority.

The European Economic Area ("EEA"): research is distributed by CLSA Europe BV, authorised and regulated by the Netherlands Authority for Financial Markets.

CLSA Securities Malaysia Sdn. Bhd (CLSA Malaysia)'s research coverage universe spans listed securities across the FBM KLCI Index, securities listed on offshore markets, unlisted issuers and investment products which Research management deem to be relevant to the investor base from time to time. CLSA Malaysia seeks to cover companies of relevance to its domestic and international investor base across a variety of sectors.

For all other jurisdiction-specific disclaimers please refer to <https://www.clsa.com/disclaimer.html>. The analysts/contributors to this report may be employed by any relevant CLSA entity or CLST, which is different from the entity that distributes the report in the respective jurisdictions. © 2024 CLSA and/or CL Securities Taiwan Co., Ltd. ("CLST").

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.